New subgroup analysis from the Phase 3 monarchE trial that explores outcomes by nodal status for Verzenio plus endocrine therapy in HR+, HER2– high-risk early breast cancer INDIANAPOLIS, Nov. 24, 2025 ...
The results from Studies A and B were published in The Journal of Allergy and Clinical Immunology.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈